share_log

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5: Prospectus

Allarity Therapeutics | 424B5：募资说明书
美股SEC公告 ·  05/02 21:43

Moomoo AI 已提取核心信息

Allarity Therapeutics Inc. has filed a prospectus supplement on May 2, 2024, to increase the maximum aggregate offering price of its common stock from $7,250,000 to $10,000,000. This amendment is in accordance with the At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC. The company has already sold $7,222,741 worth of common stock within the last 12 months and is now eligible to sell an additional $2,855,314. The prospectus supplement, which amends the prior prospectus dated November 29, 2023, and supplemented on March 19, 2024, specifies that the company will not sell more than one-third of the aggregate market value of its common stock held by non-affiliates in any 12-month period, which is capped at $10,078,055, as long as the public float remains below $75 million. The filing also notes the high degree of risk involved in investing in their common stock and includes a reference to the risk factors detailed in the prior prospectus supplement.
Allarity Therapeutics Inc. has filed a prospectus supplement on May 2, 2024, to increase the maximum aggregate offering price of its common stock from $7,250,000 to $10,000,000. This amendment is in accordance with the At-The-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC. The company has already sold $7,222,741 worth of common stock within the last 12 months and is now eligible to sell an additional $2,855,314. The prospectus supplement, which amends the prior prospectus dated November 29, 2023, and supplemented on March 19, 2024, specifies that the company will not sell more than one-third of the aggregate market value of its common stock held by non-affiliates in any 12-month period, which is capped at $10,078,055, as long as the public float remains below $75 million. The filing also notes the high degree of risk involved in investing in their common stock and includes a reference to the risk factors detailed in the prior prospectus supplement.
Allarity Therapeutics Inc.已于2024年5月2日提交了招股说明书补充文件，将其普通股的最高总发行价从725万美元提高到1,000万美元。该修正案符合与Ascendiant Capital Markets, LLC签订的市场发行销售协议。在过去的12个月中，该公司已经出售了价值7,222,741美元的普通股，现在有资格再出售2855,314美元。招股说明书补充文件修订了先前于2023年11月29日发布的招股说明书，并于2024年3月19日进行了补充。该补充文件规定，只要公众持有量保持在7500万美元以下，公司在任何12个月期间出售的普通股总市值的三分之一都不会超过非关联公司持有的普通股总市值的三分之一，上限为10,078,055美元。该文件还指出了投资普通股所涉及的高度风险，并提到了先前的招股说明书补充文件中详述的风险因素。
Allarity Therapeutics Inc.已于2024年5月2日提交了招股说明书补充文件，将其普通股的最高总发行价从725万美元提高到1,000万美元。该修正案符合与Ascendiant Capital Markets, LLC签订的市场发行销售协议。在过去的12个月中，该公司已经出售了价值7,222,741美元的普通股，现在有资格再出售2855,314美元。招股说明书补充文件修订了先前于2023年11月29日发布的招股说明书，并于2024年3月19日进行了补充。该补充文件规定，只要公众持有量保持在7500万美元以下，公司在任何12个月期间出售的普通股总市值的三分之一都不会超过非关联公司持有的普通股总市值的三分之一，上限为10,078,055美元。该文件还指出了投资普通股所涉及的高度风险，并提到了先前的招股说明书补充文件中详述的风险因素。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间